RETEVMO (selpercatinib)
TherapyEli Lilly
RETEVMO (selpercatinib) from Eli Lilly is a targeted inhibitor for tumors driven by RET alterations.
Approvals
5
Indications
4
Biomarkers
1
Mapped tests
3
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and RETEVMO. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where RETEVMO is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung | RET
| View testing pathway → | |
Medullary Thyroid Cancer (MTC) Solid Tumor · Thyroid | RET
| View testing pathway → | |
Thyroid Cancer (TC) Solid Tumor · Thyroid | RET
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for RETEVMO.
| Level | Biomarker criteria | Notes | |
|---|---|---|---|
| Solid Tumors | RET
|
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering RETEVMO for eligible patients.
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
Oncomine Dx Target Test
Life Technologies Corporation (ThermoFisher Scientific)
Method
NGS
Specimen
Tissue (FFPE)
3 approvalsView test profile →
Test
TruSight Oncology Comprehensive
Illumina, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →